Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

Open access
Volkmann, Elizabeth R, Tashkin, Donald P, Sim, Myung, Li, Ning, Goldmuntz, Ellen, Keyes-Elstein, Lynette, Pinckney, Ashley, Furst, Daniel E, Clements, Philip J, Khanna, Dinesh, Steen, Virginia, Schraufnagel, Dean E, Arami, Shiva, Hsu, Vivien, Roth, Michael D, Elashoff, Robert M, Sullivan, Keith M · 2019 · Annals of the Rheumatic Diseases

Abstract

Objective To assess survival and identify predictors of survival in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung Studies (SLS) I and II. Methods SLS I randomised 158 patients with SSc-ILD to 1 year of oral cyclophosphamide (CYC) vs placebo. SLS II randomised 142 patients to 1 year of oral CYC followed by 1 year of placebo vs 2 years of mycophenolate mofetil. Counting process Cox proportional hazard modelling identified variables associated with long-term mortality in SLS I and II. Internal validation was performed using joint modelling. Results After a median follow-up of 8 years, 42% of SLS I patients died, and when known the cause of death was most often attributable to SSc. There was no significant difference in the time to death between treatment arms in SLS I or II. Higher baseline skin score, older age, and a decline in the forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLCO) over 2 years were independently associated with an increased risk of mortality in SLS I. The Cox model identified the same mortality predictor variables using the SLS II data. Conclusion In addition to identifying traditional mortality risk factors in SSc (skin score, age), this study demonstrated that a decline in FVC and DLCO over 2 years was a better predictor of mortality than baseline FVC and DLCO. These findings suggest that short-term changes in surrogate measures of SSc-ILD progression may have important effects on long-term outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2018-213708

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 197

Metadata

Authors
Volkmann, E. R., Tashkin, D. P., Sim, M., Li, N., Goldmuntz, E., Keyes-Elstein, L., Pinckney, A., Furst, D. E., Clements, P. J., Khanna, D., Steen, V., Schraufnagel, D. E., Arami, S., Hsu, V., Roth, M. D., Elashoff, R. M., & Sullivan, K. M.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2019-01
Volume
78
Issue
1
Pages
122-130
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2900158663
Cited by
197
References
1
FWCI
14.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. https://app.cochat.ai/papers/10.1136/annrheumdis-2018-213708
The paper
Volkmann, E. R., Tashkin, D. P., Sim, M., Li, N., Goldmuntz, E., Keyes-Elstein, L., Pinckney, A., Furst, D. E., Clements, P. J., Khanna, D., Steen, V., Schraufnagel, D. E., Arami, S., Hsu, V., Roth, M. D., Elashoff, R. M., & Sullivan, K. M. (2019). Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-213708

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.